Trial Profile

MK-5684-004: A Phase 3, Randomized, Open-label Study of Opevesostat Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment With One Next-generation Hormonal Agent (NHA) (OMAHA-004)

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 15 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dexamethasone (Primary) ; Fludrocortisone (Primary) ; Opevesostat (Primary) ; Abiraterone; Enzalutamide; Hydrocortisone; Hydrocortisone; Prednisone
Indications Adenocarcinoma; Prostate cancer
Focus Registrational; Therapeutic Use
Acronyms MK-5684-004; OMAHA2a
Sponsors Merck Sharp & Dohme

04 Jun 2024 Trial design presented at the 60th Annual Meeting of the American Society of Clinical Oncology
05 Jan 2024 According to a Merck & Co media release, company announced initiation of this study.
27 Dec 2023 Status changed from not yet recruiting to recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com